BGB 324

Drug Profile

BGB 324

Alternative Names: BGB-324; R-428

Latest Information Update: 26 Dec 2016

Price : $50

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer BerGenBio; University of Texas Southwestern Medical Center
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer
  • Phase I Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Solid tumours
  • Preclinical Pancreatic cancer

Most Recent Events

  • 08 Dec 2016 BerGenBio plans a clinical trial for Breast cancer (Combination therapy)
  • 05 Dec 2016 Clinical data from a phase I trial in Acute myeloid leukaemia presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
  • 05 Dec 2016 Clinical data from a phase I trial in Myelodysplastic syndrome presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top